Radiotherapy with cetuximab or durvalumab for advanced HNSCC
1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the...
Read More
Oncology
Refining Fracture Risk Assessment for Patients With Cancer
FRAX has been validated for fracture risk assessment for patients with cancer, with HRs indicating an association between FRAX scores and fracture risk.
Read More
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
1. The median progression-free survival was 15.0 months in the inavolisib and 7.3 months in the...
Read More
Emphasizing Societal Benefits of Clinical Trials May Improve Minority Enrollment
Underscoring how trials can benefit all members of a community and discussing spirituality may improve enrollment of Black patients in cancer clinical trials.
Read More
Improving Post-Polypectomy Screening
Fecal immunochemical tests for post-polypectomy colorectal cancer surveillance may reduce the need for colonoscopy and improve screening adherence.
Read More
Induction chemotherapy followed by chemoradiotherapy improves survival in advanced cervical cancer
1. 5-year progression-free survival was increased in the induction chemotherapy group compared to...
Read More
Nivolumab Does Not Improve Post-ICI Therapy Progression-Free Survival in Advanced Renal Cell Carcinoma
1. No significant difference was seen regarding progression-free survival between the...
Read More
Pembrolizumab with chemoradiotherapy improves survival in locally advanced cervical cancer
1. 36-month overall survival was significantly greater in the pembrolizumab-chemoradiotherapy...
Read More
Perioperative Pembrolizumab Improves Survival in Resectable Early-Stage Non-Small Cell Lung Cancer
1. 36-month overall survival and median event-free survival were significantly greater in the...
Read More
Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving radiotherapy
1. In a cohort of individuals with invasive ductal carcinoma (IDC) that underwent...
Read More
Combination of doxorubicin-trabectedin with trabectedin improves leiomyosarcoma outcomes
1. In patients with advanced leiomyosarcoma, a regimen of doxorubicin-trabectedin was superior to...
Read More
Extended Pelvic Lymphadenectomy Does Not Improve Survival in MIBC
1. In this randomized controlled trial, extended lymphadenectomy did not improve disease-free or...
Read More
Liver Transplantation + Chemo Improves Survival for Unresectable Colorectal Liver Metastases
1. 5-year survival was significantly greater in the liver transplantation plus chemotherapy group...
Read More
Cabozantinib In Advanced Neuroendocrine Tumors
1. Progression-free survival had a hazard ratio of 0.38 (extrapancreatic NETs) and 0.23...
Read More
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors
1. Treatment of desmoid tumours with dual anti-CTLA-4 and anti-PD-1 blockade with ipilimumab and...
Read More
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant)....
Read More
Esophageal Cancer Disparities Declined From 1999 to 2020
From 1999 to 2020, age-adjusted esophageal cancer mortality decreased among Black adults but stabilized among White adults.
Read More
EHR Nudge Can Reduce Unnecessary Sentinel Lymph Node Biopsy
An EHR nudge intervention targeting surgeons can reduce sentinel lymph node biopsy (SLNB) among women who meet the Choosing Wisely criteria for SLNB omission.
Read More
Rare Cancers Associated With Poor Psychological Outcomes
Researchers found an increased risk ratio for depression and anxiety among patients with rare cancers, as well as higher incidences of suicide and PTSD.
Read More
Substantial Disparities Seen for Men in Cancer Cases & Deaths
Disparities seen in cancer incidence and mortality among men across age groups and countries/territories for 2022 are projected to widen further by 2050.
Read More